Cubist Pharmaceuticals, Inc. (CBST) Presents Detailed Results From Positive Phase 3 Trials Of Ceftolozane/Tazobactam At 2014 European Congress Of Clinical Microbiology and Infectious Diseases (ECCMID)
5/12/2014 9:17:35 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the first detailed results from positive pivotal Phase 3 clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Results will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Barcelona May 10 - 13.
Help employers find you! Check out all the jobs and post your resume.
comments powered by